DOCSLIB.ORG

Treating Tobacco Use and Dependence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treating Tobacco Use and Dependence Treating Tobacco Use and Dependence HPB-MOH Clinical Practice Guidelines 1/2013 Academy of Medicine, College of Family Physicians, Ministry of Health, Singapore Singapore Singapore Singapore Armed Forces Pharmaceutical Society Singapore Dental Medical Corps of Singapore Association Singapore Medical Singapore Nursing Singapore Psychological Association Association Society May 2013 Levels of evidence and grades of recommendation Levels of evidence Level Type of Evidence 1++ High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias. 1+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias. 1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias. 2++ High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal. 2+ Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal. 2- Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal. 3 Non-analytic studies, e.g. case reports, case series 4 Expert opinion Grades of recommendation Grade Recommendation A At least one meta-analysis, systematic review of RCTs, or RCT rated as 1++ and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results. B A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+ C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2++ D Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+ GPP Recommended best practice based on the clinical experience of the guideline (Good Practice development group. Points) CLINICAL PRACTICE GUIDELINES Treating Tobacco Use and Dependence HPB-MOH Clinical Practice Guidelines 1/2013 Published by Health Promotion Board, Singapore 3 Second Hospital Avenue Singapore 168937 Copyright © 2013 by Health Promotion Board, Singapore ISBN 978-981-07-6314-5 Available on the Health Promotion Board website: http://www.hpb.gov.sg/cpg-smoking-cessation and Ministry of Health website: http://www.moh.gov.sg/cpg Statement of Intent These guidelines are not intended to serve as a standard of medical care. Standards of medical care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge advances and patterns of care evolve. The contents of this publication are guidelines to clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not ensure a successful outcome in every case. These guidelines should neither be construed as including all proper methods of care, nor exclude other acceptable methods of care. Each physician is ultimately responsible for the management of his/her unique patient, in the light of the clinical data presented by the patient and the diagnostic and treatment options available. Contents Page Executive Summary and Key Guideline Recommendations 1 1 Introduction 6 2 Suggested Framework for Treating Tobacco Use and Dependence 13 3 Tobacco Use and Dependence Treatment Approaches: 19 Non-pharmacological Interventions 4 Tobacco Use and Dependence Treatment Approaches: 27 Pharmacotherapy Interventions 5 Treatment and Management of Specific Populations a. Hospitalised & Pre-operative Patients 33 b. Adolescents 36 c. Pregnant Women 37 d. Patients with Psychiatric Disorders 39 e. Patients with Cardiovascular Disease 40 f. Patients with Co-morbid Alcohol Abuse 42 6 Clinical Quality Improvement 43 7 Cost-effectiveness of Tobacco Use and Dependence Interventions 44 Annexes a. Annex A: Drug Dosages and Adverse Effects 45 b. Annex B: List of Tobacco Use and Dependence 48 Treatment Services References 59 Self-assessment (MCQs) 68 Workgroup Members 70 Acknowledgment 72 List of Endorsing Agencies 73 Foreword Globally, the use of tobacco continues to cause significant harm to human health and is a leading cause of preventable death. Tobacco use increases the risk of diseases such as lung cancer, chronic obstructive airway disease and cardiovascular disease, which are key contributors to the burden of disease in Singapore. Since the 1970s, Singapore has been active in combating tobacco use and has implemented policies on tobacco control as part of the National Tobacco Control Programme. In our latest national health survey in 2010, we achieved a smoking prevalence of 14.3% – one of the world’s lowest. This is a testament to our efforts and strategies towards tobacco control. In our continuing battle against tobacco use, health professionals play a unique role in encouraging Singaporeans to live a smoke-free lifestyle. These revised guidelines aim to equip health professionals with current scientific evidence and knowledge on interventions to help smokers quit tobacco use. I hope these guidelines will assist all health professionals to deliver effective interventions to help tobacco users become tobacco-free. PROFESSOR K SATKU DIRECTOR OF MEDICAL SERVICES Foreword Over the years, the Health Promotion Board (HPB) has established comprehensive tobacco control measures together with the Ministry of Health to promote smoke- free lifestyle among Singaporeans. The multi-pronged strategy consists of four main areas, namely taxation and legislation, public education, collaborative partnerships and capacity building, and provision of smoking cessation services. The development of Clinical Practice Guidelines (CPG) is a key strategy introduced to build the capacity of health professionals to guide their practice. The first CPG on smoking cessation was published in 2002 and the current CPG updates the evidence and recommendations for non-pharmacological and pharmacological interventions. It also focuses on specific populations that may require additional considerations (for example, pre-operative patients, adolescents, and pregnant women). A panel of health experts was convened to develop this CPG and I would like to take this opportunity to thank the CPG workgroup for their valuable contribution. In addition to medical doctors, these guidelines were produced with allied health professionals like pharmacists, nurses, and counsellors in mind. We hope that the guidelines will prove useful for all in their daily practice. MR ZEE YOONG KANG CEO, HEALTH PROMOTION BOARD Executive Summary and Key Guideline Recommendations Executive Summary Treating tobacco use and dependence is an important public health goal that will improve the quality of care and the health of all Singaporeans. The primary goal of the clinical practice guidelines is to reduce the prevalence of tobacco use and dependence through cessation treatments. There is strong evidence to show that tobacco use causes many chronic diseases such as ischaemic heart disease, stroke, multiple cancers, respiratory diseases and complications during pregnancy, that affect the population and the health delivery system. This updated Clinical Practice Guidelines on Treating Tobacco Use and Dependence is developed to act as a resource and guide for all health professionals to identify and screen tobacco users, to deliver evidence-based tobacco use cessation treatments for patients and specific population groups who use tobacco. Specific populations include hospitalised and pre-operative patients, adolescents, pregnant women, and patients with psychiatric disorders, cardiovascular diseases or alcohol abuse disorder. The guidelines are developed based on comprehensive literature reviews on recent evidence on tobacco use and dependence treatments. A suggested framework for treating tobacco use and dependence has also been developed to provide a simple step-by-step approach that all health professionals can use. The important message to every health professional is to make treating tobacco use and dependence a priority during the patient’s visit. It is important that you ask your patient two key questions: a) “Do you smoke?” b) “Do you want to quit?” – followed by the use of the recommendations as listed in the various sections of the guidelines. 1 Key Guideline Recommendations Details of recommendations can be found in the main text at the pages indicated. Non-pharmacological interventions Different forms of person-to-person behavioural support including individual, A group and telephone support may be used as interventions to treat tobacco use and dependence. (pg 20) Grade A, Level 1+ If resources are available, telephone support provided separately or as part of A tobacco use and cessation intervention, should be offered to smokers undergoing a quit attempt. (pg 20) Grade A, Level 1+ Where feasible, health professionals should provide multiple behavioural A support sessions to treat tobacco use and dependence; with each session lasting more than 10 minutes. (pg 21) Grade A, Level 1+ Behavioural interventions such as motivational interviewing or cognitive B behavioural therapy may be used to help tobacco users
Load more

Recommended publications
  • Tobacco Use Patterns and Attitudes in Singapore Young Male Adults Serving Military National Service: a Qualitative Study
    Open access Original research BMJ Open: first published as 10.1136/bmjopen-2020-039367 on 28 September 2020. Downloaded from Tobacco use patterns and attitudes in Singapore young male adults serving military national service: a qualitative study Clive Tan ,1,2 Lavinia Lin,2 Mervyn Lim,1,2 Seeu Kun Ong,1 Mee- Lian Wong,2 Jeong Kyu Lee2 To cite: Tan C, Lin L, Lim M, ABSTRACT Strengths and limitations of this study et al. Tobacco use patterns Objectives To explore tobacco use patterns and factors and attitudes in Singapore influencing tobacco use in young Singaporean men serving ► This is the first qualitative study to explore multi- young male adults serving military national service. military national service: a level factors that influence tobacco-use behaviour Methods A qualitative study using in- depth telephone qualitative study. BMJ Open in young men serving military national service (or interviews and maximum variation sampling was 2020;10:e039367. doi:10.1136/ national servicemen) in Singapore. conducted with 29 Singaporean men who have completed bmjopen-2020-039367 ► Use of purposeful random sampling stratified by their national service in 2017–2018. Data were analysed selected criteria on ethnicity and educational level ► Prepublication history for using thematic analysis. in the study design allowed for inclusion of diverse this paper is available online. Results More than half (51.7%) of the participants started To view these files, please visit groups of national servicemen, to provide rich infor- smoking before age 18, with a mean age of smoking the journal online (http:// dx. doi. mation of tobacco use.
    [Show full text]
  • Temporary Compliance Waiver Notice the Linked Files May Not Be Fully Accessible to Readers Using Assistive Technology
    Temporary Compliance Waiver Notice The linked files may not be fully accessible to readers using assistive technology. We regret any inconvenience that this may cause our readers. In the event you are unable to read the documents or portions thereof, please email [email protected] or call 1-877-287-1373. Philip Morris Products S.A. THS Page 1 PMI Research & Development 2.7 Executive Summary MRTPA Section 2.7 Executive Summary Confidentiality Statement Confidentiality Statement: Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris International. Philip Morris Products S.A. THS Page 2 PMI Research & Development 2.7 Executive Summary TABLE OF CONTENTS 2.7.1 EXECUTIVE SUMMARY .....................................................................................9 2.7.2 PROPOSED MODIFIED RISK AND MODIFIED EXPOSURE CLAIMS ........15 2.7.3 MODIFIED RISK TOBACCO PRODUCTS AND HARM REDUCTION .........17 2.7.4 PRODUCT DESCRIPTION AND SCIENTIFIC RATIONALE ..........................19 Development Rationale and Product Description for THS ............................................19 Heating Instead of Burning Reduces Harmful Constituents ......................................19 Product Description ...................................................................................................20
    [Show full text]
  • Heated Tobacco Products' Reduced Exposure Claims
    Research paper Tob Control: first published as 10.1136/tobaccocontrol-2018-054324 on 12 September 2018. Downloaded from Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims Lucy Popova,1 Lauren Kass Lempert,2 Stanton A Glantz2,3 ► Additional material is ABStract As of February 2018, the new HTPs, like PMI’s published online only. To view Introduction Heated tobacco products (HTPs) are IQOS, were being sold in multiple countries around please visit the journal online being marketed in several countries around the world the world in minimalist high-tech looking stores (http:// dx. doi. org/ 10. 1136/ 5–7 tobaccocontrol- 2018- 054324). with claims that they are less harmful than combusted that resemble Apple stores. Advertisements and cigarettes, based on assertions that they expose users marketing materials for IQOS emphasise both its 1School of Public Health, to lower levels of toxicants. In the USA, Philip Morris superiority over combustible cigarettes (in terms Georgia State University, International (PMI) has submitted an application to the of cleanliness and customisability) and similarity Atlanta, Georgia, USA 2Center for Tobacco Control Food and Drug Administration (FDA) in 2016 seeking to them (in terms of product’s taste, size and 6 Research & Education, authorisation to market its HTPs, IQOS, with reduced risk providing similar behavioural experience). Claims University of California, San and reduced exposure claims. about health benefits or lower risks of IQOS are not Francisco, California, USA Methods We examined the PMI’s Perception and emphasised in the marketing materials and some of 3Department of Medicine, Cardiovascular Research Behavior Assessment Studies evaluating perceptions of the materials carry minimal health warnings, such Institute, Philip R.
    [Show full text]
  • PMI Powerpoint Presentation
    Investor Day – Asia Region Lausanne, June 23, 2010 Matteo Pellegrini President, Asia Region Philip Morris International Agenda ● Operating environment ● PMI strategic priorities in Asia ● Brand portfolio and innovations ● Key Asia markets: highlights ● Questions & Answers 2 Operating Environment 2009 • Population : 3.8 billion Korea Japan • Cigarette Volume: 3.4 trillion China Taiwan Cigarette Volume: Pakistan Hong Kong 1.2 trillion units (Excl. – China) Others 15% India Bangladesh Indonesia Thailand Philippines 22% Vietnam Bangladesh 6% Malaysia Pakistan Singapore 6% Vietnam Indonesia 7% Japan 20% Australia Philippines New Zealand 7% Korea 8% India Asia accounts for 56% of the world’s population 9% And 60% of the world’s cigarette volume… Note: Cigarette volumes reflect 2009 Source: Global Insights 3 GDP Per Capita in 15 Key Markets ($ 000) 50 43.9 39.9 36.4 30.4 USA US $ 46,300 European Union US $ 33,100 Asia Pacific US $ 4,000 17.2 16.5 7.0 Asia: $ 4.0 3.9 3.5 2.3 1.8 1.1 1.0 0.9 0.6 0 India China Japan Taiwan Vietnam Thailand Pakistan Malaysia Australia Indonesia Singapore Philippines Hong Kong Bangladesh South Korea Source: Global Insights 4 GDP Growth and Unemployment Rates (%) Japan (%) Australia 7 7 7 7 5.1 4.7 4.1 5.6 3.8 4.0 5.2 4.8 4.4 2.0 2.3 2.0 4.2 2008 2009 4.7 3.3 0 0 2.6 2006 2007 2010 F 2.4 (1.2) 1.3 (5.2) (7) (7) 0 0 GDP Growth Rate 2006 2007 2008 2009 2010 F Unemployment Rate (%) Indonesia (%) Philippines 12 12 12 12 10.3 9.1 8.4 7.9 8.1 8.0 7.3 7.4 7.5 7.3 6.3 6.1 5.5 5.6 5.3 7.1 4.5 3.8 4.2 0.9 0 0 0 0 2006 2007 2008
    [Show full text]
  • Unmanufactured Tobacco, Burley
    Foreign Agricultural Service GAIN Report Global Agriculture Information Network Voluntary Report - public distribution Date: 11/30/2000 GAIN Report #PO0032 Portugal Tobacco and Products Annual 2000 Approved by: Robert Wicks U.S. Embassy, Madrid Prepared by: Leonor Ramos Report Highlights: Portuguese 2000 tobacco output is to remain at 6,193 Mt, farm weight basis, and in 2001 at forecast 6,111 Mt. A boosted industrial activity is to lead to an expansion of 2000 total un-manufactured tobacco imports up to estimated 15,000 Mt, and of 2001 imports up to forecast 17,000 Mt. Tobacco imports from the U.S. are to reach estimated 7,500 Mt in 2000, and forecast 8,100 Mt in 2001. 1 USD = 236 Pte. Includes PSD changes: Yes Includes Trade Matrix: Yes Unscheduled Report Madrid [SP1], PO GAIN Report #PO0032 TABLE OF CONTENTS Executive Summary .....................................................1 Commodity Name: Unmanufactured Tobacco, Total ..................................2 Production, Supply & Distribution Table .....................................2 Production ............................................................2 Consumption ..........................................................3 Trade .................................................................4 Policy ................................................................7 Production Quotas .................................................7 Prices and Subsidies ................................................8 Marketing .............................................................9
    [Show full text]
  • Smoking Report.Indd
    The prevalence of tobacco use Tobacco and health in Wales June 2012 Tobacco and health in Wales 1 A technical guide explaining the data sources and methods used in this report, plus interactive spreadsheets containing additional data at health board and local authority level, are available at: www.publichealthwalesobservatory.wales.nhs.uk/tobaccoandhealth Project team (analysis and writing): Hugo Cosh, Gareth Davies, Ioan Francis, Elinor Griffiths, Leon May, Cath Roberts, Claire Tiffany, Margaret Webber Project board: Mererid Bowley, Nathan Lester, Cindy Marsh, Cath Roberts, Jane Wilkinson Acknowledgements Thanks to the following people for their contribution to this report: Rose Allgeier, Joanna Arthur, Susan Belfourd, Lloyd Evans, Deirdre Hickey, Ciarán Humphreys, Louise Megrath, Isabel Puscas, Salah Sharif (NHS Information Centre) Contact details Public Health Wales Observatory 14 Cathedral Rd Cardiff CF11 9LJ Email: [email protected] Website: www.publichealthwalesobservatory.wales.nhs.uk For further information or to request printed copies of this report, please contact us. Publication details / copyright statement Title: Tobacco and health in Wales Publisher: Public Health Wales NHS Trust / Welsh Government Date: June 2012 ISBN: 978-0-9572759-0-4 All tables, charts and maps were produced by the Public Health Wales Observatory and Welsh Government. Data sources are shown under each graphic. Material contained in this report may be reproduced without prior permission provided it is done so accurately and is
    [Show full text]
  • Case No COMP/M.3191 - PHILIP MORRIS / PAPASTRATOS
    EN Case No COMP/M.3191 - PHILIP MORRIS / PAPASTRATOS Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 02/10/2003 Also available in the CELEX database Document No 303M3191 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 02/10/2003 SG (2003) D/232408 In the published version of this decision, PUBLIC VERSION some information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of MERGER PROCEDURE business secrets and other confidential ARTICLE 6(1)(b) DECISION information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a To the notifying parties general description. Dear Sir/Madam, Subject: Case No COMP/M.3191 - PHILIP MORRIS/PAPASTRATOS Notification of 2.9.2003 pursuant to Article 4 of Council Regulation No 4064/891 1. On 2.9.2003, Philip Morris Holland BV notified its intention to acquire control of the whole of Papastratos Cigarette Manufacturing SA (“Papastratos”) within the meaning of Art 3(1)b of the Merger Regulation. 2. The Commission has concluded that the notified operation falls within the scope of the Merger Regulation as amended and does not raise serious doubts as to its compatibility with the common market and with the functioning of the EEA Agreement. I. THE PARTIES 3. Philip Morris Holland BV is a subsidiary of Philip Morris International Inc. ("Philip Morris"), an affiliate of Altria Group, Inc.
    [Show full text]
  • 355.Full.Pdf
    Tob Control: first published as 10.1136/tc.2009.031153 on 27 September 2010. Downloaded from Research paper Phasing-out tobacco: proposal to deny access to tobacco for those born from 2000 Deborah Khoo,1 Yvonne Chiam,1 Priscilla Ng,1 AJ Berrick,2 HN Koong1 1Department of Surgical ABSTRACT nature of nicotine,7 which limits the effectiveness Oncology, National Cancer As a contribution to worldwide efforts towards of measures to encourage quitting, this is the group Centre Singapore, Singapore that forms the principal battleground for both sides 2Department of Mathematics, a tobacco-free society, this paper considers the National University of possibility of a long-term phasing-in of a total ban, by in the tobacco war. There is a strong trend world- Singapore, Singapore proposing that individuals born in or after the year 2000 wide for those who started smoking as teenagers to e have their supply of tobacco restricted. In conjunction, go on to become adult, long-term tobacco users.8 10 Correspondence to a survey that we have conducted in Singapore indicates Unfortunately, the ammunition provided by the HN Koong, National Cancer fi Centre Singapore, Department strong public support (even among current smokers) for measures indicated above seems to be insuf cient of Surgical Oncology. 11 the proposal. to prevent young people from taking up the Hospital Drive, Singapore smoking habit. This suggests that, although the 169610, Singapore; synergistic measures of education and legislation, [email protected] such as policies on awareness, display and promo- Received 23 April 2009 INTRODUCTION tion, warning labels, taxation, and designated Accepted 18 March 2010 Tobacco use in the form of smoking has long been smoking zones, play very important roles and 4 11 12 fi recognised as a cause of morbidity and premature should not be neglected, a signi cantly novel mortality, which incurs significant healthcare and approach may yet be needed.
    [Show full text]
  • Health Factsheet
    Health Factsheet May 30 2014, INP-14-1 A Publication of the National Registry of Diseases Office, Singapore World No Tobacco Day Information Paper Smoking is a contributory factor to many cancers and diseases. Local data shows that there is a higher proportion of smokers amongst cancer, heart attack and stroke patients than in the general population. On this World No Tobacco Day, learn more about the health effects of tobacco use and encourage smokers around you to quit. BACKGROUND Smoking is the most preventable cause of death globally. Tobacco kills nearly 6 million people each year, of which more than 600,000 are non-smokers dying from breathing second-hand smoke. If nothing is done to address tobacco use especially in developing economies, it is on track to kill more than 8 million people by year 20301,2. IMPACT OF SMOKING IN SINGAPORE A higher percentage of smokers are observed among heart attack and stroke patients as compared to the general population of Singapore residents in 2010 (Figures 1 and 2)3-7. 1 © Research & Strategic Planning, Health Promotion Board Released May 30, 2014 (INP-14-1) Figure 1: Percentage of smokers among Singapore residents and patients 30% 24% 25% 23% 20% 14% 15% 14% 11% 10% 5% 0% General Cancer patients Heart attack Stroke patients Patients with population patients kidney failure Figure 2: Percentage of smokers among Singapore residents and patients by gender 40% 36% 35% 35% 30% 25% 25% 25% 20% 20% Male 15% Female 10% 4% 4% 5% 5% 3% 1% 0% General Cancer patients Heart attack Stroke patients Patients with population patients kidney failure Sources: - National Health Survey 2010 - National Registry of Disease Office 2011 and 2012 2 © Research & Strategic Planning, Health Promotion Board Released May 30, 2014 (INP-14-1) TOBACCO PRODUCTS IN SINGAPORE The most common form of tobacco product in Singapore is cigarettes.
    [Show full text]
  • Cigarette Smoking, Social Support, and Workplace Smoke-Free Policies Among an Urban American Indian Population
    Cigarette Smoking, Social Support, and Workplace Smoke-free Policies among an Urban American Indian Population A Dissertation SUBMITTED TO THE FACULTY OF UNIVERSITY OF MINNESOTA BY Genelle Ruth Sanders Lamont IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Patricia M. McGovern, Ph.D., MPH, BSN, Advisor Jean L. Forster, Ph.D., MPH, Co-Advisor December 2017 © Genelle Ruth Sanders Lamont 2017 Acknowledgements I want to thank my advisors Dr. Pat McGovern and Dr. Jean Forster for their overwhelming support, dedication, advice, and help throughout this project. I would also like to thank committee members Dr. Nancy Nachreiner and Dr. Jeff Mandel for their thorough review of and advice on my project proposal and dissertation. Special thanks to Rose Hilk for helping me with data management and cleaning and Amanda Corbett and Lisa Skjefte for their hard work coordinating interviewer training and survey implementation. Chi mii-gwetch (many thanks) to Kris Rhodes, John Poupart, and Melanie Peterson-Hickey for connecting me with culturally sensitive methodologies and tobacco research in the American Indian community. I also extend my utmost gratitude to Andy Ryan for helping me to understand Directed Acyclic Graphs, regression models, and for SAS analyses troubleshooting. Support for this effort was provided, in part, by the National Institute for Occupational Safety and Health (NIOSH)’s Midwest Center for Occupational Health and Safety (#T42OH008434) and the Great Lakes Inter-Tribal Council Native American Research Center for Health. The Tribal Tobacco Use Prevalence Study was supported by ClearWay MinnesotaSM CARA Grant (RC-2008-0014). Also special thanks to community interviewers Lucy Arias, Deanna Beaulieu, Cameron Blacksmith, Christine Damann, Carl Fransen, Miigis Gonzalez, Indi Lawrence, Carrie Owen, Joy Rivera, Loretta Rivera, Rica Rivera, Sandra Rivera, Lisa Skjefte, Lucie Skjefte, Carla Smith, Samirya Strong, Corrie Thompson, Rachel Thompson, Felicia Wesaw, and Jacque Wilson.
    [Show full text]
  • 38 2000 Tobacco Industry Projects—A Listing (173 Pp.) Project “A”: American Tobacco Co. Plan from 1959 to Enlist Professor
    38 2000 Tobacco Industry Projects—a Listing (173 pp.) Project “A”: American Tobacco Co. plan from 1959 to enlist Professors Hirsch and Shapiro of NYU’s Institute of Mathematical Science to evaluate “statistical material purporting to show association between smoking and lung cancer.” Hirsch and Shapiro concluded that “such analysis is not feasible because the studies did not employ the methods of mathematical science but represent merely a collection of random data, or counting noses as it were.” Statistical studies of the lung cancer- smoking relation were “utterly meaningless from the mathematical point of view” and that it was “impossible to proceed with a mathematical analysis of the proposition that cigarette smoking is a cause of lung cancer.” AT management concluded that this result was “not surprising” given the “utter paucity of any direct evidence linking smoking with lung canner.”112 Project A: Tobacco Institute plan from 1967 to air three television spots on smoking & health. Continued goal of the Institute to test its ability “to alter public opinion and knowledge of the asserted health hazards of cigarette smoking by using paid print media space.” CEOs in the fall of 1967 had approved the plan, which was supposed to involve “before-and-after opinion surveys on elements of the smoking and health controversy” to measure the impact of TI propaganda on this issue.”113 Spots were apparently refused by the networks in 1970, so plan shifted to Project B. Project A-040: Brown and Williamson effort from 1972 to 114 Project AA: Secret RJR effort from 1982-84 to find out how to improve “the RJR share of market among young adult women.” Appeal would 112 Janet C.
    [Show full text]
  • Tobacco Project
    Physicians for a Smoke-Free Canada: Tobacco Project TABLE OF CONTENTS I Introduction 1 II Research Methodology 1 III Tobacco Screening Framework 1 IV Tobacco Companies and Countries of Origin 2 V Canadian Companies 6 Tobacco Manufacturers 6 Other Canadian Companies 7 VI Non-Canadian Companies 8 Michael Jantzi Research Associates Inc. Physicians for a Smoke-Free Canada: Tobacco Project I INTRODUCTION Michael Jantzi Research Associates Inc. (MJRA) tracks the social and environmental performance of Canadian companies. MJRA was retained to provide a list of Canadian firms that are involved in the manufacture of tobacco or tobacco-related products. Kinder, Lydenberg, Domini & Co., Inc. (KLD) provides social research on US corporations. KLD provided information regarding non-Canadian companies that manufacture tobacco or tobacco-related products. This report begins by exploring MJRA’s research methodology. It then describes the tobacco screen, which MJRA developed in order to define whether or not a company is involved with the manufacture of tobacco or tobacco-related products. Next, the report focuses on a table highlighting all tobacco companies and their countries of origin, before providing some additional information about the Canadian companies and non-Canadian firms identified by MJRA and KLD as having involvement in this area. II RESEARCH METHODOLOGY In reviewing and analysing the social performance of Canadian companies, MJRA utilises a comprehensive array of sources, including corporate documents and filings; major press (both national and international); periodicals, journals, and trade publications; government publications and databases; investment services databases, and our own files. MJRA analysts also conduct interviews with a wide variety of stakeholders, including community, company, industry, government, and union contacts.
    [Show full text]